Adaptive Biotechnologies (ADPT) Short-term Investments (2018 - 2026)

Adaptive Biotechnologies has disclosed Short-term Investments across 9 years of filings, most recently posting $140.8 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $140.8 million, down 1.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.8 million (down 1.42% YoY), and the FY2025 annual result was $156.5 million, down 10.26% from the prior year.
• Short-term Investments came in at $140.8 million for Q1 2026 at Adaptive Biotechnologies, down from $156.5 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $408.2 million in Q4 2022 to a low of $140.8 million in Q1 2026.
• The 5-year median for Short-term Investments is $237.6 million (2024), against an average of $239.7 million.
• Peak annual rise in Short-term Investments reached 90.74% in 2022, while the deepest fall reached 53.99% in 2022.
• Adaptive Biotechnologies' Short-term Investments stood at $408.2 million in 2022, then tumbled by 31.07% to $281.3 million in 2023, then sank by 38.02% to $174.4 million in 2024, then slipped by 10.26% to $156.5 million in 2025, then slipped by 10.05% to $140.8 million in 2026.
• The last three Short-term Investments figures came in at $140.8 million (Q1 2026), $156.5 million (Q4 2025), and $157.7 million (Q3 2025), per Business Quant data.